When competitive intelligence is predictive rather than reactive, biopharma companies can grab the edge

In the dynamic global biopharma landscape, competitive intelligence (CI) is as indispensable as ever.

Read more >

NGS, maybe, sort of, sometimes clinic ready

Detailed genomic profiling is a sine qua non of precision medicine, and at tertiary cancer centers, the comprehensive profiling of tumors and matched germline DNA is becoming ever more routine.

Read more >

Advancing evidence-based indication prioritization to navigate disease segmentation landscape

Innovation in genomic technologies over the past two decades has ushered in an explosion of new drug targets for drug discovery.

Read more >

Victories in Huntington’s disease few and far between, but resolve remains undimmed

The HD community has tempered its expectations but not its optimism.

Read more >

The 3 Rs of cancer research: rigor, reproducibility and robustness

As scientists gathered at the 2017 meeting of the American Association for Cancer Research (AACR) in Washington in early April to learn about the latest advances in cancer research, one of the questions was how much of that research would hold up to attempts to reproduce it.

Read more >